Anna Morena D’alis

Anna Morena D’alis

Company: Nouscom

Job title: Head of Preclinical and Clinical Immunology


Viral vectored vaccines targeting many neoantigens elicit effective anti-tumor T cell immunity and response in combination with anti-PD1 4:45 pm

• Nouscom proprietary engineered viral vectors encoding large number of tumor neoantigens elicit strong immune response and effectively synergize with checkpoint inhibitors (CPI) to eradicate large tumors in preclinical models • Effectiveness of vaccination is CD8 mediated and correlates with expansion and diversification of the intratumoral T cell repertoire • Clinical development in indications with…Read more

day: Day One

Development of a First-in-class Shared Neo-Antigen Vaccine for the Treatment of Prostate Cancer 4:45 pm

Data to show critical understanding of the tumor microenvironment to determine response to immune checkpoint therapy in combination with cancer vaccines Identification of VISTA as a potent inhibitory checkpoint that is predominantly expressed on CD68+ macrophages on PDACs, suggesting that VISTA may be a relevant immunotherapy target for effective treatment of patients with pancreatic cancerRead more

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.